---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-027244"
form_type: "8-K"
ticker: "MAIA"
cik: "0001878313"
company_name: "MAIA Biotechnology, Inc."
filed_at: "2025-12-11T23:59:59+00:00"
generated_at: "2026-05-16T13:32:50.512599+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC

## Summary
- First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.
- Trial targets up to 300 patients with primary endpoint of overall survival; screening underway in Taiwan, Turkey, EMA countries, Georgia.
- CEO Vitoc and board purchased ~182,445 shares on open market Nov 21–28, 2025; insiders now hold 12.95% of company.
- Phase 2 data showed median OS 17.8 months vs ~6 months for chemo; FDA granted Fast Track designation for ateganosine.

## SEC filing metadata
- accession: 0001493152-25-027244
- form_type: 8-K
- ticker: MAIA
- cik: 0001878313
- company_name: MAIA Biotechnology, Inc.
- filed_at: 2025-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1878313/000149315225027244/0001493152-25-027244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1878313/000149315225027244/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-027244
- JSON: https://secwatch.observer/filing/0001493152-25-027244.json
- Plain text: https://secwatch.observer/filing/0001493152-25-027244.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.